-
Ferring bolsters global gene therapy supply chain with European manufacturing facility
in PRESS RELEASE 2024 on…
00 -
Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study
in PRESS RELEASE 2024 onFerring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in…
-
-
Ferring Pharmaceuticals successfully launches its third Swiss Franc Bond offering for CHF 330 million
in PRESS RELEASE 2024 onAd hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals successfully launches…
-
Ferring announces results demonstrating the efficacy and safety of follitropin delta for women undergoing in vitro fertilisation using an agonist protocol
in PRESS RELEASE 2024 onFerring announces results demonstrating the efficacy and safety of follitropin delta for…
-
Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal
in PRESS RELEASE 2024 onFerring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal…
-
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
in PRESS RELEASE 2024 onLaunch of two first-in-class medicines in 2023 marks start of exciting phase…
-
Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
in PRESS RELEASE 2024 on…
PRESS RELEASE 2024
PRESS RELEASE 2024